Class Action Lawsuit Filed Against ESSA Pharma Inc. over Alleged Securities Fraud
New York, NY – Levi & Korsinsky, LLP announces that a class action securities lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of investors in ESSA Pharma Inc. (“ESSA Pharma” or the “Company”) (NASDAQ: EPIX). The lawsuit seeks to recover losses on behalf of ESSA Pharma investors who were adversely affected by alleged securities fraud between December 12, 2023, and October 31, 2024.
Class Definition
The class action is brought on behalf of all persons or entities who purchased or otherwise acquired securities of ESSA Pharma Inc. between December 12, 2023, and October 31, 2024, inclusive (the “Class Period”).
Allegations
The complaint alleges that during the Class Period, ESSA Pharma made false and misleading statements and failed to disclose material information to investors. Specifically, the Company allegedly misrepresented the progress and prospects of its clinical trials for its lead drug candidate, EPI-5895. These alleged misrepresentations led investors to purchase ESSA Pharma securities at artificially inflated prices.
Impact on Individual Investors
If you invested in ESSA Pharma during the Class Period and suffered losses, you may be entitled to recover your investment losses. It is important that you contact Levi & Korsinsky, LLP as soon as possible to discuss your potential recovery options.
Impact on the World
The securities fraud allegations against ESSA Pharma could have far-reaching consequences for the biotech industry as a whole. If the allegations are proven true, it could lead to increased scrutiny of other biotech companies and their clinical trial data. This could result in decreased investor confidence in the sector and potentially impact the valuations of other biotech companies.
Next Steps
To get more information about the ESSA Pharma class action lawsuit, or if you have any questions, please contact Joseph E. Levi, Esquire, at 212-363-7500, toll-free at 877-363-5972, or via email at [email protected]. You can also visit the firm’s website at www.zlk.com for more information.
Conclusion
The filing of this class action lawsuit against ESSA Pharma highlights the importance of accurate and transparent disclosures by publicly traded companies. Investors rely on these disclosures to make informed decisions about where to invest their hard-earned money. If you believe you have been negatively impacted by ESSA Pharma’s alleged securities fraud, contact Levi & Korsinsky, LLP to discuss your potential recovery options.
- Levi & Korsinsky, LLP files class action lawsuit against ESSA Pharma Inc.
- Allegations of securities fraud during the Class Period.
- Misrepresentations regarding clinical trial progress and prospects of EPI-5895.
- Individual investors may be entitled to recover losses.
- Far-reaching consequences for the biotech industry.
- Contact Levi & Korsinsky, LLP for more information.
